Mon, Oct 20, 2014, 5:14 AM EDT - U.S. Markets open in 4 hrs 16 mins


% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

tensgut 4 posts  |  Last Activity: Oct 16, 2014 4:02 PM Member since: Oct 14, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by homebuilder_watcher Oct 16, 2014 9:50 AM
    tensgut tensgut Oct 16, 2014 4:02 PM Flag

    Homebuilder, I am also a holder of both MDXG and OSIR. There is plenty of room for both companies to compete. Both companies have a specific niche. I believe you are a paid basher for MDXG. There are no paid bashers as far as I know on the pretty clean OSIR board except for some of the shorts and MDXG bashers.

    Now, let''s dissect Osiris's claim "the leading cellular regenerative medicine company". Did you notice that Osiris was talking about regenerative medicine, that they differentiate themselves from the competition by using living tissue, not dehydrated? Living tissue is alive and regenerates, dead tissue is dead and must rely on the surrounding living tissue to regenerate by itself. If the DFU/VLU patient exhibits some of these symptoms, lack of healthy stem cells, old, weak, poor circulation, malnourished, extremely obese, compromised immune system or in need of a much faster and effective recovery that is turbocharged with living, vigorous and healthy stem cells, there is really only one choice, Grafix. For the routine and small DFU's on the healthy young patients, then you are correct and Epifix could be a good choice. Let's celebrate the success of both companies!

  • tensgut by tensgut Sep 24, 2014 2:04 PM Flag

    Hansjörg Wyss (pronounced HAHNZ-jorg VEES) is a Swiss entrepreneur and businessman. As of 2013, Wyss ranks #123 on the Forbes list of billionaires, with a net worth of approximately $11.2 billion,[4] making him the second richest person in Switzerland behind Ernesto Bertarelli.

    Thomas Schmidheiny (born 1945) is a Swiss entrepreneur who was listed as by Forbes magazine as the 255th richest person in the world and 4th richest person in Switzerland as of 2012, when his net worth was estimated at $4.2 billion.[1] As of March 2013, he was estimated to be worth $5.5 billion by Forbes.

    Peter Friedli, age 60, is a Swiss entrepreneur and is the Chairman of the Board and co-founder of Osiris. Although not a billionaire yet, he will be in the near future.

    These guys have something in common, Money, Power, Swiss, Osiris connection and Fine Wine. I like the company I am keeping.

  • Osiris is no longer a drug company, its business is now focused on it's biosurgery products. It is now time for a rebranding, a make over, a change of name. Osiris Therapeutics Inc is wrong. Let's think of a new name, a name that better describes Osiris. How about Osiris Biosurgery Inc, or Osiris Regenerative Medicine Inc, or Osiris Biotech Inc? We need something informative and sexy. Management, are you listening?

  • Reply to

    Earnings Forecast

    by ozark580 Aug 2, 2014 7:57 AM
    tensgut tensgut Aug 5, 2014 9:36 AM Flag

    I am slightly kicking myself as I missed the really big run up in PBYI. I was fortunate to purchase 425 shares of PBYI as an IPO for $16 a share in October 2012. I sold all of my PBYI in the first three months of 2014 making a profit of over $38,000. I did not want to get greedy. As it turns out, if I held on to it, I would have made another $52,000. C'est la vie.

    I knew that Jay Moyes was on the Board of Directors of both Puma and Osiris. I have attended the annual meetings of Osiris for several years now. Jay always sits in the back row on the right hand side as you enter the conference room.

    There is a saying, follow the money. Jay Moyes is someone to follow. I also like to follow billionaires as they often are right.

8.29-0.20(-2.36%)Oct 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
NYSEFri, Oct 17, 2014 4:02 PM EDT
NewLink Genetics Corporation
NasdaqGMFri, Oct 17, 2014 4:00 PM EDT